Researcher, developer, and manufacturer of improved vitamin-D hormone therapies for treating secondary hyperparathyroidism associated with end-stage renal disease, renal osteodystrophy, osteoporosis, primary hyperparathyroidism, psoriasis, prostate cancer and breast cancer. The bulk of revenue is derived from activity in the pharmaceuticals industry. This company was capitalized by private investment. Products include vitamin-D hormone therapies.